← Back to Clinical Trials
Recruiting NCT07130760

NCT07130760 Intraligamentary vs Inferior Alveolar Nerve Block for Pulpitis: A Randomized Clinical Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07130760
Status Recruiting
Phase
Sponsor Aula Dental Avanzada
Condition Symptomatic Irreversible Pulpitis (SIP)
Study Type INTERVENTIONAL
Enrollment 52 participants
Start Date 2025-06-20
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Intraligamentary InjectionInferior Alveolar Nerve Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 52 participants in total. It began in 2025-06-20 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multicenter randomized trial compares the clinical effectiveness of intraligamentary injection versus inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis in mandibular molars. The goal is to determine which technique provides better pain control during endodontic treatment.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years or older * Presenting with symptomatic irreversible pulpitis in a mandibular molar * Vital response to cold testing * Ability to understand and provide informed consent * Available for follow-up and data collection Exclusion Criteria: * Known allergy to lidocaine or epinephrine * Pregnancy or breastfeeding * Use of analgesics or anti-inflammatory drugs in the previous 6 hours * Non-vital or previously treated teeth * Significant systemic disease (ASA III or above) * History of psychiatric or neurological disorders affecting pain perception

Contact & Investigator

Central Contact

Guillem Esteve-Pardo, PhD

✉ guillem@clinicaesteve.com

📞 34965215755

Frequently Asked Questions

Who can join the NCT07130760 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Symptomatic Irreversible Pulpitis (SIP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07130760 currently recruiting?

Yes, NCT07130760 is actively recruiting participants. Contact the research team at guillem@clinicaesteve.com for enrollment information.

Where is the NCT07130760 trial being conducted?

This trial is being conducted at Ferrol, Spain, Alicante, Spain.

Who is sponsoring the NCT07130760 clinical trial?

NCT07130760 is sponsored by Aula Dental Avanzada. The trial plans to enroll 52 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology